---

Highlights for July 2018

1. Cipla through its South African subsidiary, Medpro South Africa, has acquired 100% stake in Mirren Pty for US$33 Million.
2. Lupin, Boehringer Ingelheim to co-market two oral anti-diabetic drugs in India.
3. Dr. Reddy’s ties up with UCB to market epilepsy drug in India.
4. Glenmark inks pact with Seqirus to commercialise Ryaltris in Australia, New Zealand.
5. Aurobindo acquires Apotex Inc's businesses in 5 European countries for US$86 Million.
6. Catalent extends expansion with US$133 Million deal for Juniper Pharmaceuticals.
7. Otsuka to acquire antibody developer Visterra in US$430 Million deal.
8. Axovant licenses Benitec muscular dystrophy drug, continuing pivot toward gene therapies.
   Dermavant inks US$330 Million deal for GSK's phase 3-ready psoriasis drug.
9. PTC Therapeutics inks US$200 Million Agilis takeover to snag late-phase gene therapy.
10. Bayer to sell prescription dermatology unit and transfer 450 employees to Leo Pharma.
11. Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate.
12. Clinigen buys Novartis’ cancer drug Proleukin, eyes new combos.
13. Boston Scientific buys up cardiac cryoablation device firm Cryterion for US$202 Million upfront.

Updates at Aagami: 

1. New Client Win: Raising Funds for a life-saving, abuse deterrent and pain killing late stage Opioid Drug.
2. Aagami CEO finalized his forthcoming business trip to South Korea (Sep 3-7) and Japan (Sep 10-14). Meeting calendar is open, with 4 more available time options.